Clinical Trial Update: An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis [Phase 2]

View source ↗

Summary

Phase 2 extension study evaluating safety and anti-leukemic effects of imatinib mesylate in Philadelphia chromosome-positive chronic myeloid leukemia in blast c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Philadelphia Chromosome-positive Leukemia

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Philadelphia Chromosome Positive CML | Phase 2 | Status: COMPLETED | Results posted: 2021-06-25